Genezen to license CSL’s lentiviral vector production system
Pharmaceutical Technology
FEBRUARY 21, 2024
Contract development and manufacturing organisation Genezen has announced plans to license CSL’s Cytegrity lentivirus production system.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharmaceutical Technology
FEBRUARY 21, 2024
Contract development and manufacturing organisation Genezen has announced plans to license CSL’s Cytegrity lentivirus production system.
Pharmaceutical Technology
DECEMBER 5, 2022
Women’s healthcare company TherapeuticsMD has sign ed agreements for licensing its products to the Mayne Pharma affiliate in the US. Additionally, TherapeuticsMD will grant Mayne the exclusive license to market Annovera in the US. TherapeuticsMD will also get a 20-year royalty stream linked to Mayne’s net product sales.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 2, 2023
South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology. Additionally, the company will have an option to license Alteogen’s Hybrozyme technology for two more products.
Bio Pharma Dive
FEBRUARY 1, 2024
The agreement gives Protagonist an experienced hand in Takeda, which can help the former commercialize its product.
Pharmaceutical Technology
DECEMBER 8, 2022
The delivery of the product is anticipated to begin early next year. By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.
Pharmaceutical Technology
APRIL 13, 2023
The initial agreement between Dyadic and Rubic involved discovery, development, manufacturing, and distribution of Covid-19 vaccines by transferring and licensing of C1 platform technology. The now expanded agreement will enable Rubic to explore other therapeutic avenues in both the human and animal health product markets.
Pharmaceutical Technology
JUNE 19, 2023
Indian pharmaceutical company Laurus Labs has signed a memorandum of agreement (MoA) with the Indian Institute of Technology, Kanpur (IIT Kanpur) to bring new gene therapy products to the market. Laurus Labs will be responsible for launching these products in India and emerging markets.
Fierce Pharma
DECEMBER 8, 2022
TherapeuticsMD lays off entire workforce after licensing products out for $153M. Thu, 12/08/2022 - 15:35.
Camargo
AUGUST 5, 2020
Whether you plan to out-license or commercialize your product, getting the label right matters. The post Developing Drug Products with the Label’s Commercial Value in Mind appeared first on Camargo.
Pharma Mirror
APRIL 18, 2023
Dudley, UK, April 18th 2023: Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
Pharmaceutical Technology
MARCH 21, 2023
Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. Additionally, Nurix will receive up to low double-digit tiered royalties on the net sales of the product.
Scienmag
APRIL 28, 2021
— Licensing expert Bob Westervelt, who has worked to transfer Sandia National Laboratories technologies in the medical, solar and hydrogen production fields, received the 2021 Outstanding Technology Transfer Professional Award from the Federal Laboratory Consortium.
Pharmaceutical Technology
JUNE 20, 2023
The US Food and Drug Administration (FDA) has now granted fast-track and rare paediatric disease designations, and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has also granted promising innovative medicine status to vamorolone for DMD.
Pharmaceutical Technology
MARCH 10, 2023
Sandoz, a division of Novartis , has signed a Memorandum of Understanding (MoU) for constructing a new biologics production plant in Lendava, Slovenia, to support the growing demand for biosimilar medicines worldwide. At Sandoz, we are determined to continue leading the way in driving access to these critical medicines.
Pharmaceutical Technology
JUNE 19, 2023
Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar. It plans to seek regulatory approval from the European Medicines Agency, the China National Medical Products Administration and the US Food and Drug Administration.
Drug Discovery World
AUGUST 2, 2023
Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. ” The post Renaissance Pharma licenses Hu14.18
Pharmaceutical Technology
JULY 28, 2022
Rezafungin for injection received Qualified Infectious Disease Product (QIDP) designation from the US Food and Drug Administration (FDA) earlier, which gives the NDA priority review. The post Melinta and Cidara sign licensing deal for rezafungin appeared first on Pharmaceutical Technology.
Pharmaceutical Technology
OCTOBER 4, 2022
Shionogi will waive royalty payments on product sales in all countries under this deal as long as Covid-19 is listed by the World Health Organization as a Public Health Emergency of International Concern. The post Shionogi and MPP enter Covid-19 antiviral licensing deal appeared first on Pharmaceutical Technology.
Drug Discovery World
MAY 31, 2024
Jaguar Health’s out-licensing agreement with Magdalena Biosciences to develop novel, natural prescription medicines derived from plants for mental health indications, has been expanded. ” The US schizophrenia market is projected to grow to $8.06 billion by 2030, according to a market research report by Market Research Future. “The
Pharmaceutical Technology
JANUARY 23, 2023
The China National Medical Products Administration (NMPA) approved fruquintinib for marketing in September 2018. The post Takeda signs licensing agreement with HUTCHMED for fruquintinib appeared first on Pharmaceutical Technology. It was commercially launched in the country in the same year under ELUNATE brand name.
Bio Pharma Dive
AUGUST 1, 2023
Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.
Pharmaceutical Technology
MARCH 17, 2023
Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin). Under the deal, Pharmanovia will acquire the exclusive rights and license to commercialise Ghryvelin in the EEA and the UK from Consilient Health.
Pharma Mirror
APRIL 13, 2021
Wolff”) and the Spanish pharmaceutical company Cantabria Labs (“Cantabria Labs”) concluded a strategic partnership on March 12th 2021 by entering into an exclusive licensing agreement for a newly developed medicinal product for the treatment of hyperhidrosis.
BioTech 365
NOVEMBER 18, 2021
Algenex and Biokit renew licensing agreement for insect-based production of human in vitro diagnostics Algenex and Biokit renew licensing agreement for insect-based production of human in vitro diagnostics PRESS RELEASE Algenex and Biokit renew licensing agreement for insect-based production of … Continue reading →
Bio Pharma Dive
MAY 13, 2022
The agreement, which covers three experimental vaccines as well as several key patents, will be royalty free for products sold in 49 low-income countries.
Drug Discovery World
MAY 8, 2023
UK company Tay Therapeutics has entered into an exclusive license agreement with US biotech VYNE Therapeutics for its oral bromodomain and extra-terminal domain (BET) inhibitor TAY-B2. Tay Therapeutics out-licensed its topical pan-BET inhibitor to VYNE for £16m in upfront and milestone payments in 2021.
Fossil Remedies
OCTOBER 16, 2022
To launch the best PCD pharma franchise company, you will have to acquire the necessary licenses from authorities. The next important thing is the license. Every pharma company needs a drug license number to begin distribution, marketing, and manufacturing activities. License required to start a Pharmaceutical Business in India.
FDA Law Blog
FEBRUARY 5, 2024
HP&M has been helping clients navigate the challenges of state licensing regulations for drugs, biologics, medical devices, OTCs, 503B outsourcing facilities, 503A pharmacies, foods, dietary supplements, cannabis, and wholesalers/distributors for many years. Keup has joined the firm to assist attorneys Karla L.
BioTech 365
JUNE 23, 2021
Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group Acquires all royalty rights to Maxigesic® IV Assumes sole responsibility for HY-075 and HY-038 … Continue reading →
BioTech 365
JUNE 29, 2021
Plant Veda Receives License from CFIA to Produce Branded Products at New Facility Plant Veda Receives License from CFIA to Produce Branded Products at New Facility VANCOUVER, British Columbia–(BUSINESS WIRE)–Plant Veda Foods Ltd. CSE:MILK) (the “Company” or “Plant Veda”), an … Continue reading →
BioPharma Reporter
JULY 6, 2022
Touchlight has agreed to a non-exclusive patent license for Pfizer to utilize its enzymatic doggybone DNA (dbDNA).
BioTech 365
MARCH 16, 2021
Optimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch Optimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch –Company Introduces Celebrity Wellness Expert Harley Pasternak as Advisor VANCOUVER, British Columbia, … Continue reading →
Drug Patent Watch
OCTOBER 12, 2021
International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions. This paper was originally published by Md.
BioPharma Reporter
DECEMBER 7, 2023
Symbiosis Pharmaceutical Services can now test small molecule, biological and advanced therapeutical medicinal products (ATMP) following a Â1 million investment.
BioTech 365
DECEMBER 21, 2021
ITM and ANSTO Announce Extension of Licensing Agreement for the Production and Supply of the Medical Radioisotope n.c.a. Lutetium-177 ITM and ANSTO Announce Extension of Licensing Agreement for the Production and Supply of the Medical Radioisotope n.c.a. Lutetium-177 MUNICH & … Continue reading →
Camargo
DECEMBER 15, 2020
Whether a sponsor develops a new product or plans to license an exciting new asset developed somewhere else, commercial success or failure will depend on its understanding of the market and ability to develop an effective commercial strategy. What are they already prescribing for the product’s indication?
BioTech 365
APRIL 14, 2021
Heritage Cannabis Holdings Subsidiary CannaCure Receives Amended Sales License Allowing for the Sale of Dried Cannabis Products Heritage Cannabis Holdings Subsidiary CannaCure Receives Amended Sales License Allowing for the Sale of Dried Cannabis Products TORONTO–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp.
FDA Law Blog
APRIL 25, 2024
This Revised Draft Guidance provides considerations for manufacturers, packers or distributors (dubbed “firms”) of prescription biological reference products, biosimilar products, and interchangeable biosimilar products presenting data and information about such products in promotional materials in a truthful and non-misleading way.
BioTech 365
NOVEMBER 23, 2021
Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid® Products Covering 30 Countries in Europe Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A.
Fossil Remedies
JANUARY 19, 2022
But do we know which PCD products should we pick so that the maximum profitability is ensured? This blog is an attempt to clarify the concepts about choosing the best products. Points to consider while choosing products. Always pick products that you are comfortable with. Legally identified products. Perhaps no.
pharmaphorum
AUGUST 6, 2024
billion to the biotech.Agenus revealed BMS' decision in a Securities & Exchange Commission (SEC) filing (PDF), saying it was a result of a "broader strategic realignment of their development pipeline which involves other licensed products."
Camargo
OCTOBER 15, 2020
Often, to gain clinical trial design insights, a sponsor reviews the physician package inserts from approved New Drug Applications (NDAs) and Biologics License Applications (BLAs) with similar indications or in the same therapeutic area. Natural history data becomes critical for product development when there is no concurrent control.
XTalks
JANUARY 29, 2021
Oncology products monopolise the list of best-selling drugs. Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products.
BioTech 365
APRIL 2, 2021
Global Dry Powder Inhaler Devices Pipeline Assessment Report 2020: Major Players, Product Description, Licensing and Collaboration Details and Developmental Activities – ResearchAndMarkets.com Global Dry Powder Inhaler Devices Pipeline Assessment Report 2020: Major Players, Product Description, Licensing and Collaboration Details and … (..)
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content